Management said that the weakness in CRM was due to soft sales in pacemakers, which declined 11%, along with a 4% decline in the company's implantable cardioverter defibrillator (ICD) business. Even though the top line was broadly unimpressive, management made up for it in profitability - albeit not as great as the valuation currently commands. Nevertheless, although gross margin and operating income declined year over year, both arrived better than expected.
What's the Deal With ICD?
The ICD business has been St. Jude's biggest issue lately, given that it has garnered FDA attention. In fact, it's gone as far as St. Jude receiving a written warning by the FDA regarding the safety of the company's Durata leads. However, to St. Jude's credit, the company has done pretty much everything in its power to ensure the leads are safe.
Not only has the company placed the leads through rigorous tests before their launch, St. Jude has also maintained a registry of each one so that their performances can be tracked over time. Given how well the stock has performed over the past several months, it would seem that investors are content with this effort. Besides, it doesn't seem as if the Street is concerned about potential recalls, nor are there worries that St. Jude will lose market share as a result.
The consensus is that St. Jude will emerge out of this unscathed. I remain unimpressed by the company's segmental results, where St. Jude is being outperformed by Johnson & Johnson (JNJ). Plus, given the 11% revenue decline in pacemakers, it's not a stretch to suggest that market share is being lost to (among others) Boston Scientific (BSX).